The COVID-19 disease is generally categorised in an initial viral stage and a subsequent immune response phase. The later stage is characterized by hyper inflammation associated with acute respiratory distress syndrome. This warrants the use of many immune modulators and immunosuppressive drugs, which are widely used in rheumatological practice. 

Evidence suggests Dexamethasone reduces COVID-19 related mortality, interleukin-6 inhibitors reduce the risk of cardiovascular or respiratory organ support, and baricitinib reduces recovery time in hospitalized patients requiring oxygen support. The role of glucocorticoids and other antirheumatic drugs in patients with less severe COVID-19 still need trials. 

Further evidence and reports will add to the clinical utility and optimal dose and timing of other anti-rheumatic drugs in the management of COVID-19.